Results 1 to 10 of about 8,187 (238)

Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae From Bloodstream Infections in Patients With Hematologic Malignancies in China.

open access: yesMicrobiology Spectrum, 2022
Cefiderocol is a novel siderophore cephalosporin exhibiting potent antimicrobial activities. Although cefiderocol has not been approved in China, resistance is emerging.
Xueqing Wu, Xiaoting Hua, Lan Peng
exaly   +3 more sources

In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution [PDF]

open access: yesAntimicrobial Agents and Chemotherapy
Chromosomal AmpC variants selected during ceftolozane/tazobactam or ceftazidime/avibactam therapy may affect cefiderocol activity. We evaluated the impact of the E219K substitution on cefiderocol efficacy using isogenic Pseudomonas aeruginosa pairs in a ...
Arianna Rodríguez-Coello   +14 more
doaj   +2 more sources

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

open access: yesFrontiers in Pharmacology, 2022
Cefiderocol is a novel synthetic siderophore-conjugated antibiotic that hijacks the bacterial iron transport systems facilitating drug entry into cells, achieving high periplasmic concentrations.
Yifan Wang, Deqing Yang
exaly   +3 more sources

Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa

open access: yesAntimicrobial Agents and Chemotherapy
Cefiderocol/xeruborbactam is a novel β-lactam/β-lactamase inhibitor combination in which the siderophore-cephalosporin cefiderocol is paired with xeruborbactam, a broad-spectrum inhibitor that targets class A to D β-lactamases.
Lucía González-Pinto   +10 more
doaj   +2 more sources

Relative inhibitory activities of taniborbactam and xeruborbactam against KPC variants conferring reduced susceptibility or resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam [PDF]

open access: yesAntimicrobial Agents and Chemotherapy
The emergence of KPC variants associated with ceftazidime/avibactam resistance may also compromise the activity of other recently developed β-lactams, including cefiderocol and cefepime/taniborbactam. Xeruborbactam is a boronic acid β-lactamase inhibitor
Salud Rodríguez-Pallares   +12 more
doaj   +2 more sources

Paired In Vitro Susceptibility of Cefiderocol and Colistin in Colistin-Resistant, Extensively Drug-Resistant Gram-Negative Bacilli: A Single-Centre, MIC-Based Analysis of 236 Clinical Isolates [PDF]

open access: yesMicroorganisms
Extensively drug-resistant (XDR) Gram-negative bacilli increasingly exhaust therapeutic options, leaving colistin and cefiderocol as last-resort agents.
Elena Hogea   +6 more
doaj   +2 more sources

Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli Before Its Approval in China: A Report From China CRE-Network.

open access: yesMicrobiology Spectrum, 2022
Cefiderocol has been approved in the United States and Europe but not in China. We aim to evaluate carbapenem-resistant Enterobacterales (CRE) susceptibility to cefiderocol to provide baseline data and investigate the resistance mechanism.
Longyang Jin, Hui Wang, Yuyao Yin
exaly   +3 more sources

Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020–2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program

open access: yesMicrobiology Spectrum
Cefiderocol and the β-lactam/β-lactamase inhibitor (BL-BLI) combinations ceftazidime-avibactam (CAZ-AVI), imipenem-relebactam (IMI-REL), and ceftolozane-tazobactam (TOL-TAZ) are recommended for the treatment of difficult-to-treat resistance (DTR ...
John H. Kimbrough   +8 more
doaj   +2 more sources

PiuA promoter mutations confer cefiderocol resistance in Acinetobacter baumannii: from in vitro evolution to global genomic screening [PDF]

open access: yesFrontiers in Microbiology
IntroductionCarbapenem-resistant Acinetobacter baumannii (CRAB) poses a global health threat due to limited therapeutic options. Cefiderocol, a novel siderophore-conjugated cephalosporin, demonstrates potent in vitro activity against a variety of Gram ...
Xiaochen Liu   +12 more
doaj   +2 more sources

Cefiderocol

open access: yesRevista Española de Quimioterapia, 2022
Cefiderocol is a new siderophore cephalosporin with potent in vitro activity against gram-negative bacilli including Enterobacterales that produce all kinds of carbapenemases and non-fermenting Gram-negative with difficult-to-treat resistance. As a β-lactam, its efficacy is optimized in extended-perfusion and requires dose adjustment in renal ...
Soriano, María Cruz   +2 more
  +5 more sources

Home - About - Disclaimer - Privacy